Johnson & Johnson INLEXZO Gets J-Code for Cancer Access
RARITAN, N.J., USA — April 1, 2026 Johnson & Johnson announced that its innovative bladder cancer therapy INLEXZO™ (gemcitabine...
NMIBC
Advertisement
MVR-T3011 Posts 100% RFS in BCG-Naïve NMIBC
SUZHOU, China, February 26, 2026 ImmVira Group announced encouraging preliminary clinical data for its oncolytic virus candidate MVR-T3011 in...
CG Oncology Advances Phase 3 Timeline for NMIBC Trial
IRVINE, California | January 9, 2026 — CG Oncology, Inc., a late-stage clinical biopharmaceutical company, has announced an accelerated...
INLEXZO Shows 74% One-Year Disease-Free Survival in High-Risk NMIBC
NEW BRUNSWICK, NJ — December 2025 — Johnson & Johnson announced new one-year results showing that its intravesical gemcitabine...
Advertisement
